- Home
- AUTL vs HUMA Comparison
AUTL vs HUMA Comparison
Compare AUTL & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- HUMA
- Stock Information
- Founded
- AUTL 2014
- HUMA 2004
- Country
- AUTL United Kingdom
- HUMA United States
- Employees
- AUTL N/A
- HUMA N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- HUMA Health Care
- Exchange
- AUTL Nasdaq
- HUMA Nasdaq
- Market Cap
- AUTL 625.4M
- HUMA 367.6M
- IPO Year
- AUTL 2018
- HUMA N/A
- Fundamental
- Price
- AUTL $2.47
- HUMA $2.34
- Analyst Decision
- AUTL Strong Buy
- HUMA Strong Buy
- Analyst Count
- AUTL 5
- HUMA 7
- Target Price
- AUTL $9.32
- HUMA $13.00
- AVG Volume (30 Days)
- AUTL 1.8M
- HUMA 3.4M
- Earning Date
- AUTL 08-07-2025
- HUMA 08-12-2025
- Dividend Yield
- AUTL N/A
- HUMA N/A
- EPS Growth
- AUTL N/A
- HUMA N/A
- EPS
- AUTL N/A
- HUMA N/A
- Revenue
- AUTL $9,011,000.00
- HUMA $517,000.00
- Revenue This Year
- AUTL $461.76
- HUMA N/A
- Revenue Next Year
- AUTL $112.66
- HUMA $896.45
- P/E Ratio
- AUTL N/A
- HUMA N/A
- Revenue Growth
- AUTL N/A
- HUMA N/A
- 52 Week Low
- AUTL $1.11
- HUMA $1.15
- 52 Week High
- AUTL $5.00
- HUMA $9.79
- Technical
- Relative Strength Index (RSI)
- AUTL 69.22
- HUMA 50.49
- Support Level
- AUTL $2.24
- HUMA $2.13
- Resistance Level
- AUTL $2.53
- HUMA $2.80
- Average True Range (ATR)
- AUTL 0.13
- HUMA 0.18
- MACD
- AUTL -0.00
- HUMA 0.01
- Stochastic Oscillator
- AUTL 88.55
- HUMA 35.69
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.